Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

466
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
466
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

440
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
440

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity <i>In Vivo</i>.

Journal of medicinal chemistry·2026
Same author

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Cell·2026
Same author

Ancestral Wuhan SARS-CoV-2 anti-spike CD4<sup>+</sup> T cells predict protection from symptomatic omicron breakthrough infection.

Vaccine·2026
Same author

Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

[Role of resident memory T cell subpopulations in anti-tumour vaccination and cancer immunotherapy].

Medecine sciences : M/S·2025

Related Experiment Video

Updated: Mar 14, 2026

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.3K

In Silico Adjuvant Design and Validation.

Matthew N Davies1, Helene Pere2,3, Iris Bosschem4

  • 1Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, Division of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG, UK.

Methods in Molecular Biology (Clifton, N.J.)
|October 9, 2016
PubMed
Summary
This summary is machine-generated.

Novel small molecules targeting CCR4 were identified to enhance vaccine efficacy. These compounds block regulatory T cells, boosting protective immune responses in preclinical models.

Keywords:
AdjuvantCCR4Dendritic cellsRegulatory T cellSmall moleculeVaccine in silico

More Related Videos

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
08:15

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

2.3K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K

Related Experiment Videos

Last Updated: Mar 14, 2026

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.3K
In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
08:15

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

2.3K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K

Area of Science:

  • Immunology
  • Vaccinology
  • Computational Biology

Background:

  • Adjuvants enhance vaccine immune responses, but many are discovered empirically.
  • Regulatory T cells (Tregs) suppress immune responses crucial for vaccine effectiveness.
  • CCR4 is a chemokine receptor on Tregs, binding CCL22 and CCL17 produced by antigen-presenting cells.

Purpose of the Study:

  • To identify novel adjuvants with defined mechanisms using an in silico approach.
  • To develop small molecule antagonists targeting CCR4 on Tregs.
  • To evaluate the adjuvant potential of CCR4 antagonists in enhancing vaccine responses.

Main Methods:

  • Utilized an in silico approach combined with immunoregulatory knowledge.
  • Identified and validated small molecule antagonists for CCR4.
  • Assessed Treg migration inhibition in vitro and in vivo.
  • Tested CCR4 antagonists as adjuvants in vaccine models.

Main Results:

  • Successfully identified small molecule CCR4 antagonists.
  • Demonstrated inhibition of Treg migration by CCR4 antagonists.
  • Showed significant enhancement of protective immune responses when CCR4 antagonists were combined with vaccine antigens in experimental models.

Conclusions:

  • Small molecule CCR4 antagonists represent a novel class of adjuvants.
  • Targeting Treg migration via CCR4 inhibition can enhance vaccine efficacy.
  • This approach offers a mechanism-based strategy for novel adjuvant discovery.